insulin glargine and lixisenatide

CHEBI:CHEBI_753123

Drug Classification

Important Medical Information

⚕️ This information is sourced from ChEBI (Chemical Entities of Biological Interest) database and is intended for educational purposes only.

  • Always consult with a healthcare professional before starting, stopping, or modifying any medication.
  • Side effects may vary and this list may not be comprehensive.
  • Drug interactions may occur with other medications.

Additional Identifiers

🔍 Click on any linked disease name to learn more about the conditions this medication is used to treat, or explore related drug classifications for more information about similar medications.

Additional Attributes

rxcui
1859000
product_type
HUMAN PRESCRIPTION DRUG
listing_expiration_date
20251231
dosage_form
INJECTION, SOLUTION
route
SUBCUTANEOUS
marketing_category
BLA
nui
M0160181
pharm_class_epc
GLP-1 Receptor Agonist [EPC]
pharm_class
Glucagon-Like Peptide 1 [CS]
pharm_class_cs
Glucagon-Like Peptide 1 [CS]
active_ingredient_name
LIXISENATIDE
unii
74O62BB01U
pharm_class_moa
Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]
active_ingredient_strength
33 ug/mL
marketing_start_date
20161121
package_marketing_start_date
20161121
labeler_name
sanofi-aventis U.S. LLC
manufacturer_name
sanofi-aventis U.S. LLC
generic_name
insulin glargine and lixisenatide
brand_name
Soliqua 100/33
brand_name_base
Soliqua 100/33
product_ndc
0024-5761
application_number
BLA208673
spl_id
c6838c6b-44f0-4013-8d26-9c342b336e1c
package_ndc
0024-5761-05
package_description
5 SYRINGE in 1 CARTON (0024-5761-05) / 3 mL in 1 SYRINGE (0024-5761-02)
spl_set_id
4bba538b-cf7c-4310-ae8f-cb711ed21bcc
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class